Chief Executive Officer
Dr. Joslyn served as Chief Executive Officer, President & Director of Oragenics Inc. until May 2021.
Since 2009 he has served as Board member of Synergy Pharmaceuticals (NASDAQ: SGYP). Since 2014, Dr. Joslyn has been a partner in Lazarus Pharmaceuticals, LLC. From March 2010 to April 2014, Dr. Joslyn served as CEO and a Director of Sentinella Pharmaceuticals and from August 2009 to October 2012 as CEO and Director of Edusa Pharmaceuticals, both privately held biotechnology companies.
From March 2007 to March 2009, Dr. Joslyn served as President and Chief Executive Officer of Mt. Cook Pharma and as Senior Vice President of Research & Development at Penwest Pharmaceuticals from 2004 to 2007. From 1995 to 2004, Dr. Joslyn held a number of leadership positions within Johnson & Johnson and Glaxo focusing on development of gastroenterology products including Propulsid®, Motilium®, Aciphex®, prucalopride and Zofran. Dr.
Joslyn received his B.S. in medicinal chemistry, B.A. in biology and Ph.D. in biochemical pharmacology from the State University of New York at Buffalo.
Chief Scientific and Strategy Officer and Cofounder of Inimmune
Dr. Evans is the Chief Scientific and Strategy Officer and Cofounder of Inimmune Corp. Dr. Evans is also Director of the Center for Translational Medicine at the University of Montana and a Research Professor in the Division of Biological Sciences.
He has over 20 years’ experience in the biotechnology and pharmaceutical industry including 15 years at GlaxoSmithKline Vaccines (formerly Corixa Corporation) where he held various roles including North American Pre-Clinical Innovation Team Leader, Project Leader, and Investigator. Dr. Evans completed his Postdoctoral Fellowship at the University of Texas Southwestern Medical Center and St. Jude Children’s Research Hospital working in HIV immunology, stem cell transplantation, and vector-based gene therapy systems. Dr. Evans holds a Ph.D. in Molecular and Cellular Biology from Oregon State University and a B.S. in Biology from Pacific Lutheran University.
Dr. David Burkhart is the Chief Operating Officer and Co-Founder of Inimmune, while also overseeing the formulation science R&D team. Dr. Burkhart was an investigator with GlaxoSmithKline for nearly 8 years leading the formulation R&D team where he demonstrated a knack for innovation and project/team management which led to his promotion from his starting role as a Principal Scientist.
Prior to his work with GSK, Dr. Burkhart was a Senior Scientist with the CMO Hollister-Stier labs in Spokane, Washington for two years where he gained invaluable experience in cGMP analytical and manufacturing. He has over 10 years of experience in the biotechnology and pharmaceutical industries with experience in project management, leadership, business development, and licensing with over 13 years experience in medicinal and analytical chemistry, formulation and drug delivery. David earned his Ph.D. in organic chemistry in 2002 from the University of Idaho and conducted research in oncology as a postdoctoral scientist at the University of Colorado, Boulder until 2005.
Michael Goguen is the founder and managing partner of Two Bear Capital, a venture capital firm in Whitefish, Montana, Boston, San Diego, and the San Francisco Bay area that invests in companies at the intersection of biotechnology, bioinformatics, artificial intelligence/machine learning and cybersecurity.
Previously, Mike was a partner at Sequoia Capital where he proved his extraordinary ability to identify and help build groundbreaking companies in Silicon Valley. Over the course of 20 years, Mike led 54 company investments to a combined market value exceeding $64 billion and had 26 exits above $100 million. He has frequently appeared on the Forbes magazine Midas List.
Mike is a noted philanthropist in Montana and serves as Vice Chairman of the Board of Trustees for Logan Healthcare, a 343-bed, 314- provider health care system headquartered in Kalispell, Montana. He holds a B.S. from Cornell University and an M.S. from Stanford University, both in Electrical Engineering.
TLR-7/8 (INI-4001), TLR-4 (INI-2002), CTLR (UM-1098), STING
Inimmune is advancing a novel TLR7/8 agonist nanoparticle formulation to the clinic to treat cancer by harnessing the patient’s immune system and synergizing with existing immune checkpoint inhibitor therapies. Further, we’re leveraging our expertise in innate immune activation to develop novel compounds and technology to target other immune receptors to develop the next generation of disruptive therapies in oncology.
Professional doctor or nurse giving flu or COVID-19 injection to patient. Woman in medical face mask getting antiviral vaccine at hospital or health center during vaccination and immunization campaign.